# colorectal cancer - deepseek-v4-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 15049
- Completion tokens: 5151
- Reasoning tokens: 0
- Total tokens: 20200
- API requests reported: 1
- Elapsed seconds: 68.463
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 1/5; original repeat 1; model vendor: DeepSeek

---
# Multidimensional Interpretation of Prognostic Transcriptomic Results in Colorectal Cancer (Overall Survival)

## 1. Overall Biological Interpretation

The current prognostic analysis of 100 unique genes in colorectal cancer (CRC) tumor tissue reveals a clear dichotomy between risk-associated (HR > 1, n=54) and protective-associated (HR < 1, n=46) genes. The dominant biological themes point toward:

**Risk-associated signature (poor OS):** A coordinated program of epithelial-mesenchymal transition (EMT) and stromal remodeling, TGF-β/BMP signaling activation, invasion-related cytoskeletal reorganization, and metabolic reprogramming toward glycolysis. Key representatives include **INHBB, ZEB1-AS1, TPM4, DCBLD2, ITGBL1, SCARA3, and SLC2A3** — genes that collectively suggest a mesenchymal, invasive, and metabolically adaptive tumor phenotype.

**Protective-associated signature (better OS):** A program of differentiated intestinal epithelial identity, mitochondrial oxidative metabolism, and intact differentiation markers. Key representatives include **CDX2, CDX1, LGALS4, MYB, ATP5B, NDUFA9, and CS** — genes that collectively suggest retention of normal colonic differentiation and oxidative bioenergetics.

The overall picture is one where loss of intestinal differentiation coupled with acquisition of mesenchymal/invasive features and metabolic flexibility portends worse survival, while preservation of epithelial differentiation and mitochondrial function is associated with better outcomes.

---

## 2. Core Biological Programs

### Program 1: Epithelial-Mesenchymal Transition and Stromal Remodeling
- **Direction:** Risk-associated (poor OS)
- **Supporting genes:** ZEB1-AS1 (HR=1.372), TPM4 (HR=1.364), DCBLD2 (HR=1.408), ITGBL1 (HR=1.299), SCEL (HR=1.254), NT5E (HR=1.313), MAP1B (HR=1.327), ADAMTS18 (HR=1.263)
- **Standardized pathway:** Hallmark Epithelial Mesenchymal Transition; Reactome "Extracellular matrix organization"
- **Rationale:** ZEB1-AS1 is a long noncoding RNA antisense to ZEB1, a master EMT transcription factor. TPM4 encodes a tropomyosin isoform associated with actin cytoskeletal remodeling in motile cells. DCBLD2 and ITGBL1 are transmembrane/ECM-associated proteins linked to mesenchymal phenotypes. NT5E (CD73) has been reported as a prognostic biomarker across multiple cancer types (PMID: 36480312). The co-occurrence of these genes with consistent direction supports a coordinated EMT/invasive program.
- **Evidence strength:** Moderate. Multiple genes with consistent direction; however, no formal enrichment analysis was performed in this dataset. The EMT interpretation is supported by literature and pathway annotations but requires external statistical validation.
- **Limitations:** Some genes (e.g., SCEL, ADAMTS18) may reflect stromal contamination rather than tumor-cell EMT per se.

### Program 2: TGF-β/BMP Signaling Activation
- **Direction:** Risk-associated (poor OS)
- **Supporting genes:** INHBB (HR=1.433), FGF19 (HR=1.291), GADD45B (HR=1.324), CYP1B1 (HR=1.285)
- **Standardized pathway:** KEGG "TGF-beta signaling pathway"; Reactome "Signaling by TGF-beta family members"
- **Rationale:** INHBB encodes the inhibin βB subunit, which forms activin B — a TGF-β superfamily ligand. High INHBB expression in CRC has been independently associated with poor prognosis (PMID: 41992239). FGF19 can crosstalk with TGF-β signaling. GADD45B is a stress-response gene that can modulate TGF-β pathway activity. The presence of these genes with risk-associated direction suggests active TGF-β/activin signaling promoting aggressive behavior.
- **Evidence strength:** Moderate. INHBB has the strongest statistical support in the entire dataset (HR=1.433, FDR=0.0011) and is supported by independent literature in CRC specifically. However, the pathway interpretation relies on literature knowledge rather than a computed enrichment.
- **Limitations:** TGF-β signaling can be context-dependent (tumor-suppressive in early stages, pro-metastatic in later stages); the current analysis cannot distinguish stage-specific effects.

### Program 3: Loss of Intestinal Differentiation and Wnt/β-Catenin Dysregulation
- **Direction:** Protective-associated (better OS)
- **Supporting genes:** CDX2 (HR=0.748), CDX1 (HR=0.781), LGALS4 (HR=0.771), MYB (HR=0.771), LGALS9 (HR=0.753)
- **Standardized pathway:** KEGG "Wnt signaling pathway"; Reactome "Transcriptional regulation by CDX2"
- **Rationale:** CDX2 and CDX1 are master transcription factors for intestinal differentiation. Loss of CDX2 is a well-established marker of aggressive CRC. CDX2 has been shown to suppress Wnt/β-catenin signaling via transactivation of GSK-3β and Axin2 (PMID: 30631044). LGALS4 (galectin-4) is a differentiation marker of intestinal epithelium. MYB is a transcription factor involved in intestinal homeostasis. The protective direction of these genes collectively indicates that retained intestinal differentiation is associated with better survival.
- **Evidence strength:** Moderate-strong. CDX2 loss as a poor prognostic marker is well-established in CRC literature. However, the current dataset provides only HR values without expression direction (log2FC), so we cannot directly confirm whether these protective genes are downregulated in tumors.
- **Limitations:** The absence of expression direction (log2FC) in this prognostic analysis limits interpretation of whether protective genes are over- or under-expressed.

### Program 4: Mitochondrial Oxidative Metabolism
- **Direction:** Protective-associated (better OS)
- **Supporting genes:** ATP5B (HR=0.748), ATP5G1 (HR=0.747), NDUFA9 (HR=0.689), CS (HR=0.755), TIMM13 (HR=0.751), COA3 (HR=0.744), OGDHL (HR=0.686)
- **Standardized pathway:** KEGG "Oxidative phosphorylation"; Reactome "The citric acid (TCA) cycle and respiratory electron transport"
- **Rationale:** Multiple nuclear-encoded mitochondrial components (ATP synthase subunits ATP5B/ATP5G1, complex I subunit NDUFA9, citrate synthase CS, mitochondrial import machinery TIMM13/COA3) show protective associations. This pattern suggests that preserved mitochondrial oxidative capacity is associated with better survival, consistent with the concept that a shift away from oxidative phosphorylation toward glycolysis (Warburg effect) is a hallmark of aggressive tumors.
- **Evidence strength:** Moderate. The consistency across multiple independent mitochondrial genes is notable, but no formal pathway enrichment was computed in this dataset.
- **Limitations:** Mitochondrial gene expression can be influenced by tumor cell content and stromal composition; these genes may not reflect functional metabolic activity.

### Program 5: Amino Acid and One-Carbon Metabolism
- **Direction:** Mixed (protective-associated predominantly)
- **Supporting genes:** ASL (HR=0.739), GLYCTK (HR=0.709), ILVBL (HR=0.725), MCCC2 (HR=0.739), ACSS2 (HR=0.758)
- **Standardized pathway:** KEGG "Glycine, serine and threonine metabolism"; KEGG "Glyoxylate and dicarboxylate metabolism" (retrieved in batch)
- **Rationale:** ASL (argininosuccinate lyase) participates in the urea cycle/arginine metabolism. GLYCTK catalyzes glycerate phosphorylation in serine metabolism. ILVBL and MCCC2 are involved in branched-chain amino acid metabolism. The protective direction of these metabolic enzymes suggests that intact amino acid catabolism may be associated with better prognosis, potentially reflecting less metabolic reprogramming.
- **Evidence strength:** Weak-moderate. The biological coherence is less clear than other programs, and the genes do not form an obvious single pathway. STRING-based interactions (e.g., GLYCTK with GRHPR, TKFC, ENO1/2/3) suggest metabolic connectivity but are not direct evidence of a coordinated prognostic program.
- **Limitations:** This program is the least well-defined and may represent multiple independent metabolic processes rather than a single coordinated program.

---

## 3. Key Genes and Interaction Modules

### 1. INHBB
- **Statistics:** HR=1.433, P=2.0e-08, FDR=0.0011 (strongest signal in dataset)
- **Role:** TGF-β superfamily ligand (activin B); within Program 2
- **Interaction type:** Pathway co-membership with other TGF-β pathway genes; literature evidence supports a functional role in CRC aggressiveness (PMID: 41992239)
- **Relationship nature:** Indirect/putative with the broader TGF-β program; no direct physical interaction data in this dataset

### 2. CDX2 (with CDX1)
- **Statistics:** CDX2 HR=0.748, P=3.0e-05, FDR=0.0355; CDX1 HR=0.781, P=9.3e-05, FDR=0.057
- **Role:** Intestinal master transcription factor; within Program 3
- **Interaction type:** Both are homeobox transcription factors with overlapping targets; literature shows CDX2 suppresses Wnt signaling via GSK-3β and Axin2 (PMID: 30631044)
- **Relationship nature:** Pathway co-membership and regulatory interaction (transcription factor → target genes); not direct physical interaction

### 3. ZEB1-AS1
- **Statistics:** HR=1.372, P=9.8e-07, FDR=0.0086
- **Role:** Antisense lncRNA to ZEB1 (EMT master regulator); within Program 1
- **Interaction type:** Regulatory interaction (antisense RNA regulating ZEB1 expression)
- **Relationship nature:** Putative regulatory interaction based on genomic context; direct physical interaction not demonstrated in this dataset

### 4. Mitochondrial Module (ATP5B, ATP5G1, NDUFA9, CS, TIMM13, COA3)
- **Statistics:** All protective-associated (HR range 0.689–0.755); NDUFA9 strongest (FDR=0.0086)
- **Role:** Mitochondrial oxidative phosphorylation machinery; within Program 4
- **Interaction type:** Direct physical interaction (ATP synthase complex, respiratory chain complexes) and pathway co-membership
- **Relationship nature:** Direct physical interaction is well-established for ATP synthase subunits (ATP5B/ATP5G1) and complex I (NDUFA9); TIMM13/COA3 are mitochondrial import/assembly factors with known physical interactions in the mitochondrial proteostasis network

### 5. TPM4
- **Statistics:** HR=1.364, P=1.3e-06, FDR=0.0089
- **Role:** Actin cytoskeletal remodeling; within Program 1
- **Interaction type:** Co-expression with EMT program genes; physical interaction with actin filaments (well-established)
- **Relationship nature:** Direct physical interaction with actin cytoskeleton (canonical function); relationship to other EMT genes is co-expression/putative

### 6. SLC2A3 (GLUT3)
- **Statistics:** HR=1.281, P=1.5e-04, FDR=0.072
- **Role:** Glucose transporter; metabolic reprogramming toward glycolysis
- **Interaction type:** Pathway co-membership with glycolytic metabolism
- **Relationship nature:** Indirect/putative relationship with the broader metabolic reprogramming program; no direct interaction with other selected genes documented

### 7. AKT3
- **Statistics:** HR=1.318, P=3.6e-05, FDR=0.0388 (7 rows in ledger)
- **Role:** PI3K/AKT signaling; cell survival and proliferation
- **Interaction type:** Pathway co-membership with multiple signaling cascades
- **Relationship nature:** AKT3 is a kinase whose direct physical substrates are well-characterized; its relationship to the EMT program is likely regulatory (phosphorylation of downstream effectors) rather than direct physical interaction with the other EMT genes

### 8. NT5E (CD73)
- **Statistics:** HR=1.313, P=4.3e-05, FDR=0.0394
- **Role:** Ectonucleotidase generating adenosine; immunosuppression; within Program 1
- **Interaction type:** Pathway co-membership with immune evasion programs
- **Relationship nature:** NT5E has been reported as a prognostic biomarker across multiple cancers (PMID: 36480312); its relationship to other risk genes is likely functional (adenosine-mediated immunosuppression) rather than direct physical interaction

### 9. MYB
- **Statistics:** HR=0.771, P=5.3e-06, FDR=0.0192
- **Role:** Transcription factor for intestinal homeostasis; within Program 3
- **Interaction type:** Regulatory interaction with CREBBP/EP300 (STRING confidence >0.99), CEBPB (0.98)
- **Relationship nature:** Direct physical interaction with transcriptional co-activators (CREBBP, EP300) is supported by STRING records; regulatory interaction with CDX2 pathway targets is putative

### 10. DCBLD2
- **Statistics:** HR=1.408, P=9.9e-07, FDR=0.0086 (direction-conflict noted in ledger; 4 rows)
- **Role:** Transmembrane protein implicated in tumor invasion; within Program 1
- **Interaction type:** Co-expression with EMT program; limited direct interaction data
- **Relationship nature:** Indirect/putative; the direction-conflict across 4 rows warrants caution in interpretation

---

## 4. Validation Priorities

### Priority 1: INHBB as a Prognostic Biomarker and Therapeutic Target
- **Classification:** Biomarker / Therapeutic target
- **Rationale:** Strongest statistical signal in the dataset (HR=1.433, FDR=0.0011); independent literature support in CRC (PMID: 41992239)
- **Current dataset evidence:** Direct survival association (risk-associated)
- **External evidence:** Published CRC-specific association with poor prognosis and malignant phenotypes (PMID: 41992239)
- **Next step:** Validate in an independent CRC cohort with OS data; assess INHBB protein expression by IHC and correlation with activin signaling markers (p-SMAD2/3)
- **Conclusion status:** Supported hypothesis (for prognostic value); exploratory (for therapeutic targeting — activin receptor inhibitors exist but efficacy in CRC is unproven)

### Priority 2: EMT/Stromal Program Composition Check
- **Classification:** Confounding or composition check
- **Rationale:** Multiple EMT-associated genes (ZEB1-AS1, TPM4, ITGBL1, DCBLD2) may reflect stromal content rather than tumor-cell EMT
- **Current dataset evidence:** Risk-associated direction for multiple EMT genes
- **External evidence:** EMT signatures in bulk RNA-seq are notoriously confounded by stromal content
- **Next step:** Perform single-cell RNA-seq or digital cytometry (CIBERSORTx) to determine whether the EMT signal originates from tumor cells or cancer-associated fibroblasts; laser-capture microdissection with RNA-seq as an orthogonal approach
- **Conclusion status:** Exploratory hypothesis

### Priority 3: CDX2/CDX1 Differentiation Axis Validation
- **Classification:** Mechanistic hypothesis
- **Rationale:** Protective association of intestinal differentiation markers; CDX2 loss is an established poor-prognosis marker in CRC; literature shows CDX2 suppresses Wnt signaling (PMID: 30631044)
- **Current dataset evidence:** Protective direction for CDX2 (FDR=0.0355) and CDX1 (FDR=0.057)
- **External evidence:** Extensive literature on CDX2 as a differentiation marker and prognostic factor in CRC
- **Next step:** IHC for CDX2 protein in the same cohort; test whether CDX2-low tumors show enrichment of the risk-associated EMT signature; functional studies (CDX2 overexpression/knockdown) to test effects on EMT gene expression
- **Conclusion status:** Supported hypothesis

### Priority 4: Mitochondrial Metabolism-Outcome Association
- **Classification:** Mechanistic hypothesis
- **Rationale:** Consistent protective direction across multiple mitochondrial genes suggests a biological program rather than noise
- **Current dataset evidence:** NDUFA9 (HR=0.689, FDR=0.0086), ATP5B (HR=0.748), ATP5G1 (HR=0.747), CS (HR=0.755), TIMM13 (HR=0.751), COA3 (HR=0.744)
- **External evidence:** Warburg effect literature supports glycolysis shift in aggressive tumors; however, mitochondrial gene expression may not reflect functional respiration
- **Next step:** Measure mitochondrial respiration (Seahorse assay) in CRC cell lines with high vs. low expression of these genes; assess whether the protective association is independent of tumor purity
- **Conclusion status:** Exploratory hypothesis

### Priority 5: AKT3 Signaling Module
- **Classification:** Interaction / network hypothesis
- **Rationale:** AKT3 (HR=1.318, FDR=0.0388) is a well-characterized oncogenic kinase with multiple downstream effectors; its role in CRC prognosis is less established than AKT1
- **Current dataset evidence:** Risk-associated direction; 7 rows in ledger suggesting multiple probes/transcripts
- **External evidence:** PI3K/AKT pathway is well-established in CRC; AKT3-specific roles are less clear
- **Next step:** Examine AKT3 isoform-specific expression by qPCR/IHC; test whether AKT3 knockdown affects EMT markers or invasion in CRC cell lines; assess p-AKT substrate phosphorylation
- **Conclusion status:** Exploratory hypothesis

---

## 5. Evidence Grounding

### Direct Evidence from Input Dataset
- HR, P, and FDR values for 100 unique genes (54 risk-associated, 46 protective-associated)
- 71 genes with FDR ≤ 0.05; 8 genes with FDR ≤ 0.01
- This is the only direct statistical evidence; no log2FC data available (prognostic analysis only)

### Pathway/Ontology Evidence
- GO/KEGG/Reactome batch retrieval identified: Regulation of phospholipase C activity, Microtubule anchoring at MTOC, Regulation of T cell migration, Glyoxylate and dicarboxylate metabolism, Melanoma, Gastric cancer
- These retrieved terms are contextual only; no formal enrichment statistics were computed
- **Independence note:** These annotations derive from curated databases that may share underlying literature; they are not independent of each other

### Protein Interaction Evidence
- STRING records exist for 73/100 selected genes
- Notable interactions: GLYCTK with GRHPR/TKFC/ENO1-3 (metabolic enzymes); MYB with CREBBP/EP300/CEBPB (transcriptional regulators); LRCH1/LRCH3 with DOCK6-8/LRCH4 (cytoskeletal regulators)
- **Independence note:** STRING integrates multiple evidence types (co-expression, experimental, text-mining); the same underlying publication may contribute to multiple edges — do not treat as independent confirmation

### Disease-Association Evidence
- INHBB: Published CRC-specific poor prognosis association (PMID: 41992239)
- CDX2: Extensive CRC literature on differentiation and Wnt suppression (PMID: 30631044)
- NT5E: Pan-cancer prognostic biomarker reports (PMID: 36480312)
- **Independence note:** These are separate publications and represent genuinely independent evidence for these specific genes, but they do not validate the entire program-level conclusions

### Expression/Tissue Evidence
- GTEx records for 81/100 genes; HPA for 75/100 genes
- These provide context for normal tissue expression but do not directly validate the tumor-specific prognostic findings

### Therapeutic Evidence
- ClinicalTrials.gov records for 32/100 genes; ChEMBL for 14/100 genes
- **Important caveat:** Drug-target relationships do not imply therapeutic efficacy in CRC. For example, mesothelin (MSLN, HR=1.313) is being explored in CAR-T therapy (PMID: 42363170), but this does not constitute evidence that MSLN targeting improves CRC survival.

### Conflicting Evidence
- DCBLD2 shows direction-conflict across 4 rows in the ledger — some probes may indicate opposite effects; this gene should be interpreted cautiously
- LOC101928747|RBMX|SNORD61 and BCL2L14 also show direction-conflicts across multiple rows

### External Statistical Validation
- **Status: Not available.** No independent cohort statistic was supplied. All program-level interpretations are supported hypotheses based on the current dataset plus contextual literature, not externally validated findings.

---

## 6. Limitations and Alternative Explanations

### Limitation 1: Tissue and Cell-Composition Differences
- Bulk tumor tissue contains variable proportions of tumor cells, stroma, and immune cells. The risk-associated "EMT" program (ZEB1-AS1, TPM4, ITGBL1, DCBLD2) may partly reflect stromal content rather than tumor-cell-intrinsic biology.
- **Investigation:** Estimate tumor purity (e.g., ESTIMATE, ABSOLUTE); perform digital cytometry or single-cell RNA-seq to assign expression to specific cell types.

### Limitation 2: Tumor Purity and Mitochondrial Gene Expression
- Protective mitochondrial genes (ATP5B, NDUFA9, CS) may be diluted in stroma-rich tumors, creating a spurious association between "low mitochondrial expression" and poor survival that actually reflects low tumor content.
- **Investigation:** Correlate mitochondrial gene expression with tumor purity estimates; validate in laser-capture microdissected epithelial compartments.

### Limitation 3: Disease Severity and Stage Confounding
- The analysis endpoint is OS, which is strongly influenced by disease stage. If stage is not adjusted in the underlying Cox model, the HRs may reflect stage differences rather than gene-specific biology.
- **Investigation:** Request stage-adjusted multivariable models; examine whether the identified genes retain significance after adjustment for stage, grade, and treatment.

### Limitation 4: Treatment Exposure
- OS is affected by treatment (surgery, chemotherapy, targeted therapy). If treatment data are unavailable, the prognostic associations may be confounded by differential treatment response.
- **Investigation:** Collect treatment history; stratify by treatment regimen; test interaction between gene expression and treatment.

### Limitation 5: Association vs. Causation and Multiple Testing
- All findings are associations. The FDR ≤ 0.05 threshold controls for false positives, but 71/100 genes passing this threshold is unusually high and may indicate correlated gene expression (e.g., co-regulated modules) rather than 71 independent biological signals. The 53 duplicated genes/probes in the ledger also inflate the effective number of tests.
- **Investigation:** Use gene-level collapsing or module-based approaches (e.g., WGCNA) to identify independent axes; validate in an independent cohort with the same endpoint.

---

## Summary Statement

The current prognostic analysis in colorectal cancer identifies a coherent risk-associated program of EMT/stromal remodeling and TGF-β/activin signaling (led by INHBB, ZEB1-AS1, TPM4) opposed by a protective program of intestinal differentiation and mitochondrial oxidative metabolism (led by CDX2, NDUFA9, ATP5B), but these conclusions remain supported hypotheses requiring independent cohort validation, cell-type-resolved analysis, and stage-adjusted modeling before they can be considered established evidence.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=50, external claims checked=0, external mismatches=0, status=passed.

Answer model API: deepseek / deepseek-v4-flash.

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
